Objective: Various lipid abnormalities are associated with Type 2 diabetes, thereby increasing the risk of cardiovascular disease and metabolic syndrome. The objective of the study is to correlate apolipoprotein ratio with insulin resistance (IR) to understand its role in Type 2 diabetes mellitus.
INTRODUCTION
Prevalence of diabetes is increasing in a alarming rate worldwide. A total of 72.1 million diabetic cases have been identified in 2013 of which 65.1 million were in India [1] . Epidemiologic studies suggest that the risk of developing dyslipidemia during lifetime is said to be increased with diabetes mellitus.
It is predicted that by 2030 diabetes mellitus may afflict up to 79.4 million individuals in India, while China (42.3 million) and the United States (30.3 million) will also see significant increases in those affected by the disease [2, 3] . At present, India faces an uncertain future in relation to the potential burden that diabetes may impose on the country [4] . Many factor influences affect and prevalence of disease throughout a country, and identification of those factors is necessary to facilitate change when facing health challenges. Genetic factors coupled with environmental influences such as obesity-associated with rising living standards, steady urban migration, and lifestyle changes contribute to the multifactorial etiology of diabetes in India [5] [6] [7] .
Dyslipidemia is one of the common disorders which are seen in most of the diabetes patients. Insulin resistance (IR) is a metabolic disorder independently associated with cardiovascular (CV) disease [8] [9] [10] . IR is associated with aging and a cluster of important cardiometabolic risk factors (dyslipidemia, arterial hypertension, hyperglycemia, and obesity) and is believed to be the common shared pathophysiological disturbance [11] [12] [13] [14] . Thus, accurate and early prediction and detection of IR are very important in clinical practice so as to identify patients at high risk for CV disorders.
ApoB and ApoA-I are the two major apolipoproteins involved in lipid transport and in the processes causing atherosclerosis and its complications [15] . ApoB100 is the main structural apolipoprotein of low-density lipoproteins (LDL) and there is only one molecule of ApoB100 per LDL particle [16] . ApoA-I reflects the antiatherogenic potential in high-density lipoprotein (HDL) particles; the higher the value, the better the protection against CV risk [17] . Therefore, in this study, we analyzed the apolipoprotein A1 and apolipoprotein B in diabetic and non-diabetic individuals and assessed the association between IR and apolipoprotein B/apolipoprotein A-I ratio in diabetic and non-diabetic individuals.
METHODS

Study population
The study population included 416 subjects individuals of which 197 were confirmed cases of Type 2 diabetes mellitus (T2DM) and remaining 219 were non-diabetic and served as control subjects under the age group of 30-60 years. Subjects were excluded if they have orthopedic limitations, weight loss/gain over the previous 6 months, or any diagnosis of vascular disease, Type 1 diabetes mellitus, cancer (clinically or by anamnesis), renal disease, liver disease, thyroid disease, and acute or chronic inflammatory diseases. Subjects consuming any medications (antihypertensive, antidyslipidemic, and antithrombotic drugs).
This study was reviewed and approved for human subjects by the Central Ethics Committee of Nitte University, Ref INST.EC/EC/47/2016-17.
Clinical measurements
Body weight and height were measured. Body mass index (BMI) was calculated as body weight in kilograms divided by height in square meters (kg/m 2 ). Venous blood samples were drawn after a minimum of 8 h of fasting. Plasma insulin level was measured commercially available enzyme-linked immunosorbent assay kits. IR was calculated with the homeostasis model assessment of IR (HOMA-IR) as described by Matthews et al. [17] (fasting serum insulin [µU/ml]×fasting serum glucose [mmol/l]/22.5). Fasting plasma glucose was measured by glucose oxidase method (LyphoCHEK ™ AGAPPE). Glycated hemoglobin (HbA1c) was measured using ion exchange resin method Kumari and Shetty on spectrophotometer (NycoCard READER). Total cholesterol (TC), triglyceride (TG), and HDL were measured using commercially available kits (LiquiCHEK ™ AGAPPE).
LDL cholesterol (LDL-C) was estimated indirectly using the Friedewald formula. ApoB and ApoA-I levels were measured using commercially available kits (Agappe).
Statistical analysis
Statistical analysis was performed with SPSS for Windows 16.0. Parametric data are presented as mean±standard deviation. For categorical values, frequency counts, and percentages were applied. For group comparisons of means, t-test was applied and significance was defined as a p<0.05.
RESULTS
The results of the study cover a total of 416 subjects of which, 197 (47.3%) were diabetic and 219 (52.6%) were non-diabetic. Of which non-diabetic group includes 23% male and 29% female, and the diabetic group includes of 28.21% male and 20% female. Table 1 represents the mean age, height, weight, BMI, FBS, HbA1c, plasma insulin, and HOMA-IR values of both non-diabetic and diabetic group FBS, HbA1c, insulin, and HOMA-IR showed a statistically significant difference between non-diabetic and diabetic individuals (p<0.05) (Tables 1-3) .
Age, BMI, fasting blood sugar (FBS), HbA1c, insulin, and HOMA-IR
Correlation between apolipoproteins, lipid ratios, and HOMA-IR in non-diabetic and diabetic group
In non-diabetic subjects, LDL/HDL ratio showed a positive correlation with HOMA-IR and negative correlation with ApoB100, whereas a negative correlation was observed between ApoA1/HDL, ApoB/LDL, and HOMA-IR. ApoB100/ApoA1 ratio also showed a positive correlation with HOMA-IR. ApoB100 showed a positive correlation with HOMA IR (Table 4 ).
In diabetic subjects, ApoB100/ApoA1 ratio also showed a positive correlation with HOMA-IR. ApoB100 showed a positive correlation with HOMA IR ( Table 5) .
Distribution of dyslipidemia based on patient characteristics
Total recruited diabetic (197) subjects with and without dyslipidemia have been characterized based on age, sex, control of diabetes, and obesity (Tables 6 and 7) .
Dyslipidemia, apolipoproteins, and HOMA-IR in diabetic group
Individual apolipoprotein levels (ApoA-1 and Apo-B100) and apolipoprotein ratios were compared in the diabetic group between dyslipidemic and non-dyslipidemic subjects. Statistically significant difference was found between dyslipidemic and non-dyslipidemic subjects with regard to ApoB100 and ApoB100/ApoA1 ratio. HOMA-IR did not show a statistically significant difference ( Table 8 ).
DISCUSSION
In diabetic cases with metabolic abnormality, disturbances in the production and clearance of plasma lipoproteins are commonly found [18] . Diabetic dyslipidemia generally comprises postprandial lipidemia, high TG, reduced HDL-C, and low or relatively normal LDL-C [19, 18] , and the development of dyslipidemia may, therefore, be a signal of future diabetes onset. Debate still exists on the nature and extent of the association between conventional lipid measures and incident Type 2 diabetes [20] .
This study is a representative of dyslipidemia and apolipoprotein ratios in diabetic and non-diabetic individuals. In the present study, we found that cholesterol, TG, LDL, HDL, and very LDL (VLDL) elevated in the diabetic group compared to the non-diabetic group.
Increased levels of TC in diabetic group compared to a non-diabetic group, maybe due to an increase in the plasma concentration of VLDL and LDL, which may be due to an increase in the hepatic production of VLDL or decreased removal of VLDL and LDL from the circulation.
On studying the deranged individual lipid parameters among Type 2 diabetic subjects with dyslipidemia, the most prevalent lipid abnormality was high LDL (68%) followed by high TG (63%). An increase in the LDL in diabetic patients may be attributed to insulin. Insulin increases the number of LDL receptor, so chronic insulin deficiency might be associated with a diminished level of LDL receptor [20] . This causes an increase in LDL particles and results in the increase in LDL-C value in diabetes mellitus. Higher levels of TG may [20] . Mixed dyslipidemia was the most common dyslipidemia pattern observed in our study.
The ApoB number indicates the total number of atherogenic particles; the higher the number, the higher the CV risk [21] . According to Barkas et al. [22] , Apo-B represents an ideal marker for the management of dyslipidemia in individuals with diabetes.
High level of total blood cholesterol, particularly in the form of LDL-C, has been recognized for over three decades as a major risk factor for developing coronary heart disease [23] . However, recent research has shown that LDL-C is not the only lipoprotein species involved in atherogenesis. Elevated levels of intermediate-density lipoprotein and also be due to insulin deficiency in hyperglycemia and mobilization of fatty acids from adipose tissue.
The current study is not in accordance with few previous studies, which showed lower levels of HDL in diabetic patients. The study done by Bodhe et al. [18] , on Indians showed that HDL-C levels varied with glycemic control. As in our study, all patients with diabetes showed higher HDL level when compared to non-diabetic individuals but were statistically insignificant. The reason for insignificant result as also suggested by Garg et al., 2016 [1] , appears that average HDL 
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VLDL are also associated with increased CV risk. All these potentially atherogenic lipoproteins contain one ApoB molecule and therefore, the total ApoB value indicates the total number of potentially atherogenic lipoproteins [24, 25] . The association of ApoB with incident Type 2 diabetes has been proven with improved risk prediction compared to LDL-C or HDL-C [24] . Thus, ApoB has been found to be a better predictor of risk than LDL-C, VLDL, and chylomicrons.
ApoA-I reflects the antiatherogenic potential in HDL particles; the higher the value, the better the protection against CV risk [26] , but the ApoA1 was lower in diabetic group, this was not in accordance to the previous studies by Onat et al., 2010 [26] who reported that high ApoA1 levels independently predicted incident Type 2 diabetes among a sample of Turkish participants.
In diabetic subjects, ApoB100/ApoA1 ratio also showed a positive correlation with HOMA-IR, suggesting that as apolipoprotein ratio increases, IR also increases. ApoB100 also showed a positive correlation with HOMA IR.
The ApoB/ApoA-I ratio indicates the balance between atherogenic and antiatherogenic particles; the higher the value, the higher the CV risk, the ApoB/ApoA1 ratio is strongly associated with IR [25] . However, only a few studies have shown the associations between apolipoprotein levels and the risk of diabetes. Hwang et al. [27] indicated that the ApoB/ApoA-I ratio is an effective predictor of T2DM in the Korean population. The ApoB/LDL-C ratio has been associated with T2DM in a population-based study of Turkish adults14 and ApoB in the Aboriginal Canadian population [28] .
CONCLUSIONS
Based on our study results, it is clear that aggressive dyslipidemia management is the need of the hour in diabetic individuals. In diabetic individuals, the overall control rate of dyslipidemia is low. The pattern of lipid profile of the study may, therefore, be a significant risk factor for the increased rate of CV problem in diabetics than normal individuals. ApoA1/ApoB-100 was highly associated with IR in both non-diabetic and diabetic groups. Further study is needed to determine the role of ApoA1/HDL-C in the development of diabetes, as susceptible individuals are increasingly considered as candidates for appropriate interventions. 
